Wednesday, May 25, 2016| Alphaeon, Blindness, Intraocular lens, IOL, IOLs, Low Vision

EyewireTV - Alphaeon Management Shakeup; IOL Growth Projections

In this week’s EyewireTV, after 3 years leading lifestyle health care company Alphaeon, Robert Grant is no longer CEO; and a new government-sponsored study predicts the number of adults in the United States with blindness or low vision will increase substantially over the next 35 years as a result of shifting demographics and an aging population. Also, due to growth in developing countries and robust demand for improved visual outcomes, ophthalmic market research company Market Scope projects strong 5-year growth in global IOL procedures.

Watch Video

Wednesday, May 18, 2016| Allergan, Bausch+Lomb, Dry Eye, Hoya Surgical Optics, Intraocular lens, IOL, IOLs, OASIS Medical

EyewireTV - B+L Expands IOL Portfolio; Allergan Tear Device Trials

In this week’s EyewireTV, Bausch + Lomb and Hoya Surgical Optics enter into an exclusive agreement under which Bausch + Lomb will distribute and commercialize Hoya’s portfolio of IOLs and injectors in the United States; and Allergan announces results of two pivotal trials of its Oculeve Intranasal Tear Neurostimulator for the increase of tear production in patients with dry eye disease. Also, Oasis Medical obtains the CE Mark for its Soft Shield collagen corneal shields.

Watch Video

Wednesday, May 11, 2016| Bausch+Lomb, digital apps, Imprimis Pharmaceuticals, IV-Free, Meibomian Gland Dysfunction, MGD, TearScience

EyewireTV - Breaking Industry News from the ASCRS Meeting In New Orleans

In this week’s EyewireTV, Imprimis Pharmaceuticals launches two new products in the ophthalmology space—an IV-free conscious sedation formulation and a triple combination eye drop; and TearScience releases the LipiScan, a high-definition gland imager that allows eye care professionals to assess meibomian gland structure during routine examinations. Also, Bausch + Lomb and IBM announce a collaboration to develop an app aimed at helping cataract surgeons streamline workflow and access patient information.

Watch Video

Tuesday, May 03, 2016| Anti-VEGF, Avastin, Carl Zeiss Meditec, Clearside Biomedical , Lucentis, Ocular Therapeutix, PLEX Elite 9000, Retina, Technology, Wet AMD

EyewireTV - Five-Year CATT Study Results; New Zeiss OCT Platform

In this week’s EyewireTV, 5-year results of the NIH-sponsored CATT study show that vision gains during the first 2 years in patients receiving Lucentis and Avastin were not maintained. However, 50% of eyes had visual acuity of 20/40 or better, confirming anti-VEGF therapy as a major long-term therapeutic advance for wet AMD; and Zeiss receives CE Mark approval for its swept-source OCT technology platform, the PLEX Elite 9000. Also, Ocular Therapeutix and Clearside Biomedical outline plans for phase 3 clinical development after reporting positive phase 2 results.

Watch Video

Wednesday, April 27, 2016| Alcon, Alcon Laboratories, Cataract Surgery, Valeant

EyewireTV - Alcon Invests in New IOL Technology; Bilateral Cataract Surgery Debated

In this week’s EyewireTV, Alcon enters into a strategic alliance with PowerVision in which Alcon will provide funding for the clinical development of PowerVision's fluid-based IOL technology; and Valeant Pharmaceuticals names Joseph C. Papa as chairman and CEO, replacing J. Michael Pearson. Also, three leading ophthalmologists share their opinions on the practicality of bilateral cataract surgery, and whether they would be open to adopting it more regularly into their practice.

Watch Video

Wednesday, April 20, 2016

EyewireTV — CXL Approved by FDA; New Femto Cannula Launched

In this week’s EyewireTV, Avedro receives FDA approval for Photrexa Viscous, Photrexa, and the KXL System for corneal collagen cross-linking in patients with progressive keratoconus; and 12-month data highlight the safety and efficacy of ab interno canaloplasty for primary open-angle glaucoma. Also, Beaver-Visitec International launches a multifunctional cannula designed to improve surgical efficiency and optimize clinical outcomes during laser cataract surgery.

Watch Video

Wednesday, April 13, 2016

EyewireTV - BromSite Approved; Ridley Innovation Centre Unveiled

In this week's EyewireTV, Sun Pharma receives FDA approval for BromSite, the first NSAID indicated for the prevention of ocular pain and treatment of postoperative inflammation in patients undergoing cataract surgery; and researchers at the USC Roski Eye Institute publish results from the largest eye study ever conducted in Chinese Americans. Also, Rayner unveils the Ridley Innovation Centre, a state-of-the-art research and development, training, and production facility with the capability of manufacturing 3 million IOLs per year.

Watch Video

Wednesday, April 06, 2016| Acquisitions, Mergers, Allergan, American Society of Cataract & Ref Surgeons, ASCRS, Corneal Collagen Crosslinking, CXL, Corneal Ectasia, FDA Approval/Clearance, Keratoconus, Pfizer, Refractive Surgery, Taxes

EyewireTV - Pfizer and Allergan Call Off Blockbuster Deal

In this week’s EyewireTV, Pfizer and Allergan decide to call off their planned $160 billion merger after the Treasury Department unveiled a series of new steps to curb tax inversions; and the FDA is expected to decide in the next 10 days whether or not to approve corneal collagen cross-linking in the UnitedStates for the treatment for progressive keratoconus and corneal ectasia following refractive surgery. Also, the American Society of Cataract and Refractive Surgery forms the ASCRS Research Council, an internal department that will collaborate with members and partners on research trials.

Watch Video

Wednesday, March 30, 2016| branded vs. generics, Teleophthalmology

EyewireTV - Concussion Eye Test Approved; Branded vs Generic Drugs

In this week's EyewireTV, Eye-Sync, a mobile device that assesses abnormal eye movement—a common deficit after a concussion—receives FDA clearance; and a new study shows that teleophthalmology may play a role in reducing coverage gaps in emergency department eye care, particularly in rural areas. In the feature, physicians discuss how important it is to prescribe branded versus generic medications and, if branded drugs are a priority, how they communicate that to the patient, who will most likely be paying a higher cost out of pocket.

Watch Video

Wednesday, March 23, 2016

EyewireTV - Valeant Management Shakeup; Cataract Progression: Diet vs. Genetics

In this week’s EyewireTV, in a major management shakeup, Valeant Pharmaceuticals announces a series of executive changes; and a large study shows for the first time that diet and lifestyle may play a greater role than genetics in cataract development and severity. Also, InnoVision Labs launches a mobile app designed to improve image processing speed, depth perception, vision sharpness, and contrast sensitivity.

Watch Video

Wednesday, March 16, 2016| Allergan, Cataract

EyewireTV - Cataract Surgery Using Stem Cells; 1-Year Raindrop Inlay Results

In this week’s EyewireTV, researchers in California and China have developed a new cataract treatment for infants that uses their own stem cells to regrow functional lenses; and Allergan is being asked by the FDA to provide additional information for its new multi-dose, preservative-free form of Restasis. Also, 1-year data from a phase 3 clinical trial of the Raindrop Near Vision Inlay show improved near visual performance and a 92% rate of satisfaction.

Watch Video

Wednesday, March 09, 2016| FDA Approval/Clearance, Glaucoma, Ophthalmic viscosurgical device, OVD, Phacoemulsification, Rayner Intraocular Lenses, Retinitis pigmentosa, Sensimed

EyewireTV - Smart Contact Lens Cleared by FDA; New Epiretinal Implant

In this week’s EyewireTV, the Sensimed Triggerfish electronic contact lens, a device that senses eye pressure changes in glaucoma patients, receives FDA clearance; and Pixium Vision announces the first implant and successful activation of the IRIS II, an epiretinal implant intended for patients who have lost sight due to retinitis pigmentosa. Also, Rayner launches a new ophthalmic viscosurgical device, Ophteis FR Pro, indicated to protect the corneal endothelium from free radical energy caused by phacoemulsification.

Watch Video
Load More